Cancer Network Staff

Adults with previously treated unresectable or metastatic non–small cell lung cancer whose tumors harbor HER2 mutations may now be treated with fam-trastuzumab deruxtecan-nxki.

Expert panelists focus on the treatment of metastatic urothelial cancer and discuss strategies and challenges for maintenance therapy.

Following 2022 ASCO GU, Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, engage in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics include most surprising new data, what needs follow-up, and shameless plug.

Around the Practice: Metastatic Castrate Resistant Prostate Cancer

Around the Practice: High-Risk Renal Cell Carcinoma

Patients with extensive-stage small cell lung cancer show greater response when atezolizumab is added to carboplatin and etoposide versus placebo in the IMpower133 trial.

Register for CancerNetwork's live, interactive event featuring leaders in oncology reviewing and discussing patient cases in breast cancer.

With the rise of precision oncology, genomic profiling is growing in its utility to support clinical decision making. Lung cancer experts can use this resource to guide therapy selection in NSCLC. Learning more about advancements in this space can improve patient outcomes and advance the field of precision oncology.

The use of PARP inhibitors in frontline maintenance therapy has greatly reduced the risk of recurrence in patients with ovarian cancer.